GRAIL Stock Tumbles - National Health Service Galleri Trial To Blame
GRAIL Inc. (NASDAQ:GRAL) shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in reducing late-stage cancer diagnoses.
NHS-Galleri Trial Results
The NHS-Galleri trial results showed a favorable trend in reducing Stage IV cancer diagnoses, although the primary endpoint was not met. On Friday, GRAIL stock closed almost 51% lower.
The trial evaluated annual multi-cancer screening with the Galleri test in England's National Health Service (NHS) over three years, involving 142,000 participants aged 50 to 77.
The results indicated a clinically meaningful reduction in Stage IV diagnoses across a group of 12 deadly cancers, with a more than 20% reduction observed in subsequent screening rounds.
The broader market experienced declines on the previous trading day, with the Russell 2000 down 0.72% and the S&P 500 falling 0.50%.
GRAIL's decline occurred while the broader market was under pressure, suggesting that the stock's movement is primarily driven by company-specific news rather than overall market trends.
GRAIL's Technical Indicators Highlight Weakness
The stock is currently trading 47.3% below its 20-day simple moving average (SMA) and 40.5% below its 100-day SMA, indicating significant short-term weakness. Shares have increased by 112.58% over the past 12 months and are currently positioned closer to their 52-week lows than highs.
The RSI is at 50.93, which is considered neutral territory, while the MACD is at 0.2738, below its signal line at 0.5506, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $52.50
- Key Support: $20.50
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $100.50. Recent analyst moves include:
- Canaccord Genuity: Buy (Lowers Target to $80.00) (Feb. 20)
- Baird: Outperform (Lowers Target to $82.00) (Feb. 20)
GRAL Price Action: Grail shares were down 2.27% at $49.07 during premarket trading on Monday.
Photo by Wirestock Creators via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Long-term contract visibility extends to 2031! HDD giant Western Digital (WDC.US) secures AI infrastructure dividends with capacity density, but "expectation cliff" causes after-hours plunge
Following the release of exceptionally strong performance data by storage chip giants Samsung and SK Hynix, as well as HDD storage leader Seagate, Western Digital’s across-the-board better-than-expected results have further reinforced the narrative of a booming “storage super cycle” led by these storage product giants.
CASHCAT jumps 22% as whale buys 16M tokens – Is $0.108 next?
Revenue Surges 53% But Shares Still Plummet! AppLovin (APP.US) Falls Over 25% After Hours Just Because Their AI Model Upgrade Was One Step Behind
After the U.S. stock market closed on Wednesday, mobile advertising giant AppLovin (APP.US) delivered a report showing a surge in profits, but was met with a harsh response from investors.
Guolian Minsheng Securities: What are US Treasuries Pricing In?
However, after entering July, due to weakening fundamentals and the Federal Reserve's hesitation on rate hikes, upward momentum on the short end has gradually slowed, while long-term rates have accelerated to new highs in comparison.
Crypto prices
More
